Advertisement

Gastro-News

, Volume 5, Issue 3, pp 46–53 | Cite as

Hepatische Eisenüberladung

Gute Prognose bei Therapie der Hämochromatose im Frühstadium

zertifizierte fortbildung

Zusammenfassung

Veränderungen verschiedener Gene können zum histopathologischen und klinischen Bild der Hämochromatose führen. In Deutschland spielt vor allem der autosomal-rezessiv vererbte HFE-Typ 1 eine Rolle, bei dem die homozygote C282Y-Mutation zu einer erhöhten intestinalen Eisenresorption und somit im Verlauf von Jahrzehnten zu Eisenablagerung und Schädigung verschiedener Organe wie Leber, Pankreas, Herz und Gelenke führt.

Literatur

  1. 1.
    Niederau C. Hemochromatosis. Chapter 23. In: Mauss S et al. (Hrsg.). Hepatology: A clinical textbook. Medizin Fokus Verlag Hamburg 2017. http://www.hepatologytextbook.com.
  2. 2.
    Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005;352:1769–78.CrossRefGoogle Scholar
  3. 3.
    Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:328–43.CrossRefGoogle Scholar
  4. 4.
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines for HFE Hemochromatosis. J Hepatol 2010;53:3-22.Google Scholar
  5. 5.
    Feder JN, Gnirke A, Thomas W, et al. A novel MCH class I-like gene is mutated in patients with hereditary haemochromatosis. Nature Genetics 1996;13:399–407.CrossRefGoogle Scholar
  6. 6.
    Daher R, Kannengiesser C, Houamel D, et al. Heterozygous mutations in BMP6 pro-peptide lead to inappropriate hepcidin synthesis and moderate iron overload in humans. Gastroenterology 2016;150:672–83.CrossRefGoogle Scholar
  7. 7.
    Daher R, Karim Z. Iron metabolism: State of the art. Transfus Clin Biol 2017 Jul 7. Epub ahead of print.Google Scholar
  8. 8.
    Finberg K, Whittlesey RL, Andrews NC. TMPRSS6 is a genetic modifier of the HFE hemochromatosis phenotype in mice. Blood 2011;117:4590–9.CrossRefGoogle Scholar
  9. 9.
    Piubelli C, Castagna A, Marchi G, et al. Identification of new BMP6 pro-peptide mutations in patients with iron overload. Am J Hematol 2017; 92:562–8.CrossRefGoogle Scholar
  10. 10.
    Niederau C, Niederau CM, Littauer A, et al. Screening for iron overload and iron deficiency. Ann Int Med 1988;128:337–5.CrossRefGoogle Scholar
  11. 11.
    Muehlenberg K, Faltermeier N, Lohse P, Tannapfel A, Pech O. Family with marked hyperferritinemia as a result of hemochromatosis type 4 (ferroportin disease). Z Gastroenterol 2014;52:1075–80.CrossRefGoogle Scholar
  12. 12.
    Phatak P, Brissot P, Wurster M, et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology 2010;52:1671–9.CrossRefGoogle Scholar
  13. 13.
    Chen LY, Chang SD, Sreenivasan GM, et al. Dysmetabolic hyperferritinemia is associated with normal transferrin saturation, mild hepatic iron overload, and elevated hepcidin. Ann Hematol 2011;90:139–43.CrossRefGoogle Scholar
  14. 14.
    Riva A, Trombini P, Mariani R, et al. Revaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome. World J Gastroenterol 2008;14:4745–52.CrossRefGoogle Scholar
  15. 15.
    Vénat L, Loustaud-Ratti V, Liozon E, et al. Dysmetabolic hepatosiderosis, characteristics in 51 patients. Presse Med J 2003;8;400–5.Google Scholar
  16. 16.
    Ruivard M, Lainé F, Ganz T et al. Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol 2009;50:1219–25.CrossRefGoogle Scholar
  17. 17.
    Murali AR, Gupta A, Brown K. Systematic review and meta-analysis to determine the impact of iron depletion in dysmetabolic iron overload syndrome and non-alcoholic fatty liver disease. Hepatol Res 2017 Jun 7. doi: 10.1111/hepr.12921. Epub ahead of print.CrossRefPubMedGoogle Scholar
  18. 18.
    Lambrecht RW, Sterling RK, Naishadham D, et al. HALT-C Trial Group. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology 2011;140:1490–500.CrossRefGoogle Scholar
  19. 19.
    Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and noncirrhotic patients with primary haemochromatosis. New Engl J Med 1985;313:1256–62CrossRefGoogle Scholar
  20. 20.
    Niederau C, Fischer R, Pürschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107–11.CrossRefGoogle Scholar
  21. 21.
    Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009;22:78–86.CrossRefGoogle Scholar
  22. 22.
    Loreal O, Deugnier Y, Moirand R, et al. Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron related factors in 127 homozygous patients. J Hepatol 1992;16:122–7.CrossRefGoogle Scholar
  23. 23.
    Niederau C, Berger M, Stremmel W, et al. Hyperinsulinaemia in non-cirrhotic haemochromatosis: impaired hepatic insulin degradation? Diabetologia 1984;26:441–4.CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Katholisches Klinikum Oberhausen, St. Josef-Hospital, Klinik für Innere Medizin, Akademisches Lehrkrankenhaus der Universität Duisburg-EssenOberhausenDeutschland

Personalised recommendations